NEWS
Endpoints News | One microcap biotech is charging headfirst into treacherous IPO waters, jumping to Nasdaq with modest raise

It’s a tough market right now for biotech IPOs, but one small company is taking the public leap Friday with a modest initial offering. Blue Water Vaccines raised $20 million in its IPO, pricing shares at $9 apiece late Thursday afternoon. The Cincinnati-based company will use the money primarily to advance a slate of preclinical […]

Technology Networks | Effective Diagnostics for Liver Disease Are Urgently Needed

Due to the increasing incidence of diabetes, obesity and metabolic disease in the United States, it is estimated that one in four patients has some form of fatty liver disease. The impact of this on the healthcare system has been realized and is likely to increase over time. As primary care physicians continue to see […]

PharmaShots | PharmaShots Interview: 180 Life Sciences’ Dr. Jim Woody Shares Insight on Repurposing Anti-TNF to Meet Unmet Needs in Pain and Inflammation

In an interview with PharmaShots, Dr. Jim Woody, MD, Ph.D., Chief Executive Officer at 180 Life Sciences shared his insights on the Phase 2b study of anti-TNF for the treatment of the early Dupuytren’s disease. Shots: 180 Life Sciences used anti-TNF to treat early Dupuytren’s disease and the Phase 2b study is complete.